Application for registration of new lung cancer drug toluenesulfonamide production of HongRi Pharmaceutical Co., Ltd. accepted
Time of Update: 2020-04-03
In the afternoon of May 19, HongRi pharmaceutical announced that the application for production registration of p-toluenesulfonamide (hereinafter referred to as "PTS") jointly
Zhengda Tianqing Pharmaceutical Co., Ltd. and BioLineRx Co., Ltd. jointly develop hepatitis C treatment drug BL-8030
Time of Update: 2020-04-03
According to the agreement, Zhengda Tianqing will obtain the follow-up development, production and sales license of bl-8030, a hepatitis C treatment drug developed by biolinerx, in mainland China and Hong Kong.
Star night rescue Co., Ltd. donated 150000 additional goggles
Time of Update: 2020-02-18
This includes 110000 pairs of goggles and 2000 thermometers donated to medical institutions in and around Wuhan and Shanghai announced on January 29.
Ruili Medical Co., Ltd. went to Hong Kong for IPO and was punished for practicing medicine without certificate and issuing prescription without certificate for many times
Time of Update: 2020-02-11
Recently, Ruili Yimei International Holding Co., Ltd
(hereinafter referred to as "Ruili Yimei") submitted IPO prospectus to the main board of the Hong Kong stock
(hereinafter referred to as "Ruili Yimei") submitted IPO prospectus to the main board of the Hong Kong stock
Northeast Pharmaceutical Co., Ltd. was selected into the list of construction units of the second batch of drug shortage centralized production base
Time of Update: 2019-12-31
[industry trends of pharmaceutical network] on December 31, the Ministry of industry and information technology released the list of construction units of the second batch
Hengrui Pharmaceutical Co., Ltd. 4 directors, supervisors and senior executives reduce shares through centralized bidding
Time of Update: 2019-12-09
Pharmaceutical intelligence news learned that on December 6, Hengrui pharmaceutical released a notice on the plan of reducing shares held by directors, supervisors and senior
Jilin Renxin Technology Co., Ltd. issued a procurement plan of 200 million yuan for coating equipment
Time of Update: 2019-11-29
At present, in order to further expand the production capacity, the company needs to expand its paint and coating production lines in four production bases of Liaoning Panjin, Hubei Xiangyang, Jiangsu Huai'an and Jiangxi Yingtan.
Shijiazhuang No.4 Pharmaceutical Co., Ltd. leads MAH enterprise, and Qilu and Huahai are "spokesmen" of consistency evaluation enterprises
Time of Update: 2019-08-14
In order to fully mobilize the enthusiasm of R & D personnel and promote drug innovation, optimize resource allocation and inhibit low-level repeated construction, implement
Actual controller of Laimei Pharmaceutical Co., Ltd. introducing state owned assets into bureau or changing to Nan'an Urban Construction Co., Ltd
Time of Update: 2019-07-09
According to the intention agreement signed between Laimei Tibet and the rescue fund, Laimei Tibet intends to transfer its 48.3054 million shares (5.95% of the total share capital of the listed company) to the rescue fund.
Zhongsheng Pharmaceutical Co., Ltd. obtained the Australian patent certificate for its products
Time of Update: 2019-06-11
See the figure below for details: This article is reprinted by yaozhi.com, and the copyright belongs to the original author.
Announcement of Heilongjiang Provincial Drug Administration on revoking the certificate of quality management standard for drug distribution of Heilongjiang Huize Pharmaceutical Distribution Co., Ltd
Time of Update: 2019-05-17
Recently, Heilongjiang pharmaceutical regulatory bureau released the cancellation of the operation quality certification of Heilongjiang Huize Pharmaceutical Distribution Co., Ltd
Taizhou rijian Sino foreign pharmaceutical industry Co., Ltd. obtained GMP certificate
Time of Update: 2019-05-16
Recently, Taizhou rijian Chinese and foreign pharmaceutical industry Co., Ltd., a settled enterprise of China Pharmaceutical City, obtained the GMP certificate issued by Jiangsu
Board of directors of Harbin Pharmaceutical Co., Ltd. decides to appoint Xu Haiying as general manager
Time of Update: 2019-03-06
Upon the nomination of general manager Ms. Xu Haiying, the board of directors of the company decided to appoint Mr. Liu Bangmin and Mr. Xiao Qiang as the deputy general manager of the company.
Yiling Pharmaceutical Co., Ltd. Wu Xiangjun: strengthen the training of general practitioners to make up for the short board of medical and health development
Time of Update: 2019-03-05
"Grass roots medical treatment is still the short board of medical and health development in China." On March 4, Wu Xiangjun, a deputy of the National People's Congress and general
Ding lieming of Beida Pharmaceutical Co., Ltd.: it is suggested to compensate for the patent period of patent innovative drugs first listed in China
Time of Update: 2019-03-04
On March 3, the first financial reporter learned that Ding liming, deputy to the National People's Congress and chairman of Beida Pharmaceutical (300558
SZ), brought 8
SZ), brought 8
China Resources Pharmaceutical Co., Ltd. indirectly holds 30% shares of Jiangzhong Pharmaceutical Co., Ltd., which has been approved by the state owned assets supervision and Administration Commission of the State Council
Time of Update: 2019-02-20
On February 20, Jiangzhong pharmaceutical announced that China Resources Pharmaceutical Co., Ltd
plans to acquire 51% equity of Jiangzhong group and become its
plans to acquire 51% equity of Jiangzhong group and become its
Kangmei Pharmaceutical Co., Ltd. and Jieyang municipal government focus on the main business of traditional Chinese medicine with many highlights
Time of Update: 2019-01-04
[China Pharmaceutical network enterprise news] on December 29, 2018, Kangmei pharmaceutical and Jieyang municipal government signed a strategic cooperation agreement
-
-
Lay out the future EGFR-TKI three generation market, and Beida Pharmaceutical Co., Ltd. will benefit from RMB 230 million of patents in the cooperation area of bio-d-0316
Time of Update: 2018-12-28
The announcement pointed out that in order to enrich the R & D product pipeline and lay out the future EGFR-TKI three generation market, through friendly consultation, Beida pharmaceutical and Yifang biology carried out cooperation on the d-0316 project.
18 enterprises in Jiangsu have obtained GMP certificates, and Jiangsu Yangzi River and Jichuan Pharmaceutical Co., Ltd
Time of Update: 2018-12-07
Jiangsu GMP certification notice (No
11, 2018) In accordance with the provisions of the administrative measures for the certification of drug production quality
11, 2018) In accordance with the provisions of the administrative measures for the certification of drug production quality
